🏛️ Verified NIH Record • Updated 2025-11-14

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (NCT05973487)

A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: TScan Therapeutics, Inc.

🩺 Plain-English Summary (8th-Grade Level)

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.

Who can join: Review the eligibility criteria below.

Location: HonorHealth Research and Innovation Institute — Scottsdale, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (21 Sites)

  • HonorHealth Research and Innovation Institute — Scottsdale, Arizona
  • University of California San Diego — San Diego, California
  • Yale Cancer Center — New Haven, Connecticut
  • Memorial Healthcare System — Hollywood, Florida
  • University of Miami, Sylvester Comprehensive Cancer Center — Miami, Florida
  • Orlando Health — Orlando, Florida
  • University of South Florida — Tampa, Florida
  • University of Chicago — Chicago, Illinois
  • Norton Cancer Institute — Louisville, Kentucky
  • Karmanos Cancer Institute — Detroit, Michigan
  • University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota
  • Columbia University Herbert Irving Comprehensive Cancer Center — New York, New York
  • University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
  • Oncology Hematology Care — Cincinnati, Ohio
  • The Cleveland Clinic — Cleveland, Ohio
  • OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
  • Providence Cancer Institute Franz Clinic — Portland, Oregon
  • Allegheny Hospitals Network — Pittsburgh, Pennsylvania
  • University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
  • Sarah Cannon Research Institute — Nashville, Tennessee
  • Baylor College of Medicine — Houston, Texas

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Head and Neck Cancer

Explore by condition: All Head and Neck Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗